Literature DB >> 32018031

Treatment of severe lichen planus with the JAK inhibitor tofacitinib.

William Damsky1, Alice Wang1, Brianna Olamiju1, Danielle Peterson1, Anjela Galan2, Brett King3.   

Abstract

Entities:  

Year:  2020        PMID： 32018031     DOI： 10.1016/j.jaci.2020.01.031

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  2 in total

Review 1.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Tofacitinib in Hypertrophic Lichen Planus.

Authors:  Peter Seiringer; Felix Lauffer; Anna Caroline Pilz; Danielle Boehmer; Tilo Biedermann; Kilian Eyerich
Journal:  Acta Derm Venereol       Date:  2020-07-28       Impact factor: 3.875
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.